By Reynaldo T. Acosta, Esq., Head of Litigation, Vitale, Suarez & Associates, P.A. · Miami Lakes, Florida
A skin substitute distributor lawsuit arrives looking like the least serious thing on your desk. It is a collection case: an invoice, a delivery record, a demand for the balance. If you are a wound care provider whose Medicare payments were recouped after you bought the product, you need to treat that filing as the most dangerous document in the sequence — because the answer you file to a contract claim can become the government’s evidence in a False Claims Act matter, and because a federal civil investigative demand frequently arrives shortly after the collection suit does.
The structure is straightforward and it is worth stating plainly. You bought product. You applied it and billed Medicare. Medicare paid, then a contractor recouped the payment. You cannot pay the distributor’s invoice, because the funds that would have paid it are gone. The distributor sues. And the lawsuit — a public filing that names the parties, the products, the quantities and the prices — becomes a map of the distribution chain.
The Sequence, and Who Described It
Writing in September 2026, Texas health law attorney Martin Merritt described this pattern from the defense side: a distributor bills a provider at a price far above what comparable products cost; Medicare pays the resulting claims; a contractor recoups the payments; and the distributor then sues the provider for the unpaid invoices, seeking a judgment the provider cannot satisfy because the money has already been taken back. Merritt further reports that the distributor’s collection suit is frequently followed closely by a federal civil investigative demand examining the seller’s business practices.
Those are observations from his practice rather than published data, and they should be weighed as such. But the structure they describe lines up with what the Department of Justice has alleged publicly, where the distribution chain is central rather than incidental.
In its national health care fraud takedown announced June 23, 2026, the Department stated that “Charges were filed against 11 defendants, including a company executive and eight medical professionals, across six districts in connection with billions of dollars in fraudulent claims for amniotic wound allografts.” It characterized the driver this way: “This significant spike in allograft billings was alleged to have been driven not by medical necessity, but by a kickback scheme that generated substantial profit margins and lavish lifestyles for marketers and providers who participated.”
Read the composition of that group. A company executive, and eight medical professionals. The Department’s public theory in this area consistently connects the seller’s incentives to the provider’s ordering — which is why a lawsuit that documents the commercial relationship between the two is not a neutral filing.
Why the Collection Case Is Legally Dangerous
The claim itself is ordinary. Breach of contract, or an account stated, or goods sold and delivered. The danger is not the cause of action. It is the interaction with two other proceedings.
The natural defense concedes the fact the government needs. The instinctive answer to a distributor’s collection claim is that the distributor misrepresented what Medicare would pay, or that the product was not what was represented, or that the pricing was not what was discussed. Those may be sound contract defenses. They also state, on the record, that you ordered and applied a product in reliance on a seller’s representation about Medicare coverage rather than on an independent medical necessity determination.
That reliance is precisely what a False Claims Act theory is built on. Under 31 U.S.C. § 3729(b)(1), “knowingly” reaches a person who “has actual knowledge of the information”, one who “acts in deliberate ignorance of the truth or falsity of the information”, and one who “acts in reckless disregard of the truth or falsity of the information” — and the definitions “require no proof of specific intent to defraud.”
Deliberate ignorance is the standard that fits a defense of “the seller told us it was covered.” The remedy is not limited to repayment: § 3729(a)(1) provides for “a civil penalty of not less than $5,000 and not more than $10,000, as adjusted by the Federal Civil Penalties Inflation Adjustment Act of 1990…plus 3 times the amount of damages which the Government sustains.”
Discovery in a private case is not private. Documents produced to the distributor’s counsel exist. Deposition testimony about how product was selected, who set the price, what the sales representative said, and what the practice understood about reimbursement all becomes a record that can be obtained. A rebate schedule or a volume-linked term produced in a commercial case is a document that answers a question a federal investigator would otherwise have to ask.
And the two matters have different clocks. A state-court answer deadline is short and unforgiving. A civil investigative demand carries its own short window. Neither waits for the other, and the one that seems least consequential usually comes due first.
The way all three proceedings interlock — the recoupment, the collection suit and the federal matter — is set out in skin graft fraud litigation and the three fronts.
The Federal Demand That Follows
If a civil investigative demand arrives, understand what it is and who can receive one.
Under 31 U.S.C. § 3733(a)(1), the Attorney General or a designee may issue a demand “before commencing a civil proceeding under section 3730(a) or other false claims law, or making an election under section 3730(b)” — before any case is filed, and before the government decides whether to intervene in a sealed whistleblower suit. A demand may require the recipient to produce documents, “answer in writing written interrogatories”, “give oral testimony”, or “furnish any combination of such material, answers, or testimony.”
The critical point is the scope of who can be served. The statute reaches “any person” who may hold relevant documentary material or information. You do not have to be the target of the investigation. A provider who purchased from a distributor under scrutiny can receive a demand about that distributor’s practices — and what you produce becomes part of the government’s own analysis. Under § 3733(i)(2), material held by the custodian may be disclosed to other agencies “for use by such agency in furtherance of its statutory responsibilities.”
If you intend to challenge a demand, the window is narrow. Section 3733(j)(2) permits a petition to modify or set it aside “within 20 days after the date of service of the civil investigative demand, or at any time before the return date specified in the demand, whichever date is earlier.” Twenty days, or less if the return date arrives sooner. What a demand involves and how a response is organized is set out in civil investigative demands.
Receiving a demand about your supplier is not an accusation against you. It is also not an invitation to explain the relationship informally.
What the Commercial Case Should and Should Not Do
Some observations that apply across this pattern. None is a substitute for advice on your own facts, and the right posture depends heavily on what the contract actually says and on what the federal picture looks like.
Read the purchase documents before you draft anything. Terms and conditions on an invoice, a distribution agreement, a pricing schedule, a rebate arrangement, a consignment term, a return or unused-product provision, and any warranty about reimbursement. The written terms determine which defenses are available and which are unavailable regardless of how the relationship actually worked.
Distinguish product defenses from reimbursement defenses. A claim that the product delivered was not the product ordered, or that quantity or condition did not match, is a defense about the goods. A claim that Medicare did not pay is a different argument with a different consequence, because it puts your billing in issue. The first category is generally safer ground.
Do not plead more than the pleading requires. A denial is a denial. Narrative explanations of what a sales representative promised, how the practice decided which product to use, or why the volume was what it was may be entirely true and still unnecessary at that stage — and once filed, they are positions rather than drafts.
Understand that the distributor may be a co-target, not a co-defendant. A seller whose practices are under federal investigation has its own exposure and its own incentives. That does not make you allies. Information sharing arrangements between parties whose interests may diverge sharply are worth approaching with care and with counsel.
Consider whether the timing of the payment dispute and the recoupment interact. A judgment for the invoice amount, entered while the government is separately recovering the corresponding payment, produces the outcome of paying twice for the same product. Whether that can be addressed depends on procedure, on the contract, and on the posture of the recoupment — which is why the appeal strategy in Medicare payment clawbacks in wound care and the defense of the collection case belong in the same conversation.
And keep the factual narrative single. One account of what happened, tested against the contract claim, the payment appeal and the federal matter before it is filed anywhere. Inconsistency across three forums is worse than an unfavorable fact in one.
The Underlying Question: What Was the Product, and What Was the Price
Two substantive issues sit beneath every one of these disputes, and both are worth understanding whichever forum you are in.
The product’s regulatory category. Under 21 C.F.R. § 1271.10(a), a human cell, tissue, or cellular and tissue-based product is regulated solely under section 361 of the Public Health Service Act only if it meets four criteria: it is “minimally manipulated”; it is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer’s objective intent”; its manufacture “does not involve the combination of the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent”; and it either lacks a systemic effect and does not depend on the metabolic activity of living cells, or meets one of the narrow autologous, close-relative or reproductive-use conditions.
The FDA states that “For HCT/Ps not meeting the criteria established in Section 1271.10, FDA premarket review (including a license, approval, or clearance) is required.”
A provider is not the manufacturer and is not responsible for a product’s regulatory status. But the category the product actually occupies is a fact about the goods you purchased, and it now affects how the product is paid: the CY 2026 rules align payment categories to FDA regulatory status, distinguishing 361 HCT/Ps, products cleared through 510(k), and products approved through premarket approval. The distinction is set out in the 361 HCT/P and 510(k) pathways.
The price, against a documented range. The OIG work plan item on Part B payments for skin substitutes, announced November 15, 2024, describes prices “ranging from approximately $100 to more than $1,000 per square centimeter.” CMS states that Part B spending on these products “rose from $252 million in 2019 to over $10 billion in 2024, a nearly 40-fold increase”, attributing most of that increase “to increases in payment rates and launch prices.” And since January 1, 2026, the Department of Justice notes, CMS has “realigned payment, reducing Medicare’s payment to $127 per square centimeter.”
The precise figure differs slightly between the physician and outpatient rules and is subject to geographic adjustment, so approximately one hundred twenty-seven dollars per square centimeter is the order of magnitude. What matters for a collection case is that there is now a public benchmark, and an invoice priced far above it is a document that invites a question in both forums.
Immediate Response Checklist
Calendar the answer deadline from the service date and give it a named owner — this is the deadline most likely to be missed while attention goes to the federal matter. Pull every purchase document: agreements, invoices, terms and conditions, pricing and rebate schedules, delivery records, and all communications with sales representatives. Preserve them, and instruct staff in writing to preserve them. Determine whether the corresponding Medicare payments were recouped, in what amount, and at what stage the appeal sits. Identify whether any federal matter is open — a demand, a subpoena, a records request, or a payment suspension. Route all communication with the distributor through counsel and stop direct contact with sales representatives about the dispute. Instruct staff not to volunteer explanations by phone or email. And do not amend or supplement clinical records after notice.
Speed matters on the answer deadline. Control matters more on everything else.
When Early Counsel Is Not Optional
A collection suit over medical supplies is, in isolation, routine commercial litigation. This pattern is not that, for three reasons.
The pleading you file in the smaller case can be used in the larger one. The federal demand that may follow reaches you whether or not you are a target, and carries a twenty-day challenge window. And the distributor across the table may be under investigation itself, with interests that diverge from yours in ways that are not visible from the complaint.
Early legal review helps coordinate the commercial defense with the payment appeal and any federal matter, control what is produced in discovery, and protect internal analysis under attorney-client privilege where applicable. Where counsel directs the review, communications about suspected legal exposure, document analysis and response strategy may be better protected than informal exchanges among clinical, billing and administrative staff.
Vitale, Suarez & Associates, P.A. has represented healthcare providers and other defendants in wound care and skin substitute matters, including audit and overpayment proceedings, commercial disputes with product suppliers, and government investigations. Nothing in this article describes any particular client, matter, or outcome. The firm’s practice in defense investigations and Medicare and Medicaid fraud defense is described among its practice areas, and the enforcement environment surrounding these products is discussed in fraud risks and provider-specific challenges in skin substitute billing.
Frequently Asked Questions
Can a distributor sue us for product Medicare refused to pay for or later recouped?
A seller can generally sue on its invoices, and whether it prevails depends on the contract and the facts. What the recoupment changes is your ability to satisfy a judgment, not the existence of the claim — which is why the collection defense and the payment appeal should be handled together.
Is it safe to defend by saying the distributor misrepresented Medicare coverage?
It may be a legitimate contract defense, and it also places on the record that you relied on a seller’s representation about coverage rather than an independent determination. Because 31 U.S.C. § 3729(b)(1) includes deliberate ignorance and reckless disregard within “knowingly”, that pleading choice should be made with the federal picture in view.
Can we receive a civil investigative demand if the investigation is about our supplier?
Yes. Under 31 U.S.C. § 3733(a)(1) a demand may be served on “any person” who may hold relevant documentary material or information. Receiving one is not an accusation against you.
How long do we have to challenge a civil investigative demand?
Section 3733(j)(2) permits a petition to modify or set it aside within 20 days after service, or at any time before the return date specified in the demand, whichever is earlier.
Is the distributor a potential ally in the federal matter?
Not necessarily. A seller under investigation has its own exposure and its own incentives, and the Department of Justice’s public allegations in this area have included company personnel alongside medical professionals. Information-sharing arrangements deserve careful evaluation with counsel.
Does an invoice price far above the current Medicare rate mean the product was overpriced?
Not by itself. Prices historically varied widely, and the OIG has described a range from approximately $100 to more than $1,000 per square centimeter. What the January 2026 realignment provides is a public benchmark that a reviewer or an opposing party will reference, which makes contemporaneous documentation of how the product was selected more valuable than it was before.
The decision rule is simple: answer the collection suit on the deadline it sets, and never plead a fact there that you would not want read aloud in the federal matter. The smallest case on your desk is the one that writes the record.
This article is for general information purposes only and should not be taken as legal advice for any individual case or situation. Reading it, or corresponding with us through this site, is not intended to create and does not create an attorney-client relationship. Federal and Florida healthcare regulations change frequently, and how any rule applies depends on the specific facts of your arrangement, your payor contracts, and your jurisdiction. Vitale, Suarez & Associates, P.A. is based in Miami Lakes, Florida and represents clients in Florida. If you have received an audit notice, records request, subpoena, civil investigative demand, or overpayment demand, speak with a licensed attorney before you respond.
Past results do not guarantee or predict a similar outcome in any future matter. Every case depends on its own facts. Charges and allegations referenced in government announcements are accusations only; a charge is not a conviction.
About the author. Reynaldo T. Acosta heads the litigation practice at Vitale, Suarez & Associates, P.A. in Miami Lakes, Florida, the firm founded in 1982 as The Health Law Offices of Anthony C. Vitale, P.A. He is a member of The Florida Bar and earned his J.D. from Florida International University College of Law, where he was named to the Dean’s List and competed on the International Commercial Arbitration and the Negotiation and Mediation teams. He also holds a B.S. in Criminal Justice and Public Management with a minor in Political Science from Florida International University, and advanced certifications in generative artificial intelligence, machine learning, and agentic systems from IBM, Anthropic, and Microsoft. He is a member of the American Bar Association, the Hispanic National Bar Association, and the Cuban American Bar Association, and works with clients in English and Spanish. More about the firm and its attorneys is available on the firm’s About page.
Contact Our Healthcare Lawyers Today!
Schedule a Consultation: (305) 358-4500
Contact Us
Vitale, Suarez & Associates, P.A.
8100 Oak Ln Suite 403
Miami Lakes, FL 33016
Phone: (305) 358-4500
Fax: (305) 358-5113
Email: info@vitalehealthlaw.com
Hours: Monday through Friday, 9:00 a.m. to 5:00 p.m.
The firm’s attorneys work with clients in English and Spanish.